Fundus laser combined with intravitreal injection of ranibizumab for patients with retinal vein occlusion secondary to macular edema

doi:10.3760/cma.j.issn.1007-1245.2023.12.017

Abstract

Abstract:

Objective　To investigate and analyze the clinical efficacy of fundus laser combined with intravitreal injection of ranibizumab (IVR) in the treatment of retinal vein occlusion secondary to macular edema (RVO-ME). Methods　Sixty patients with RVO-ME who were treated in Jinan Second People's Hospital from March 2019 to May 2022 were selected as the research objects. They were divided into an observation group and a control group by the random number table method. The observation group had 16 males and 14 females, with an age of (54.66±2.31) years. The control group had 15 males and 15 females, with an age of (54.70±2.29) years. Both groups were treated with fundus laser; in addition, the observation group were treated with IVR. The central macular thicknesses (CMT), levels of vitreous cavity related factors, best corrected visual acuities (BCVA), central choroidal thicknesses (CCT), and disease related complications were compared between the two groups. t and χ² tests were applied. Results　The CMT's in the observation group and the control group were lower after than before the treatment (F=501.71 and 303.62; both P<0.05); there were statistical differences in the CMT's at different time points after the treatment between the two groups (t=11.37, 6.71, and 5.29; all P<0.05). After the treatment, the levels of vascular endothelial growth factor (VEGF), interleukin (IL)-6, and IL-8 were lower than those before the treatment in both groups, and the levels in the observation group were lower than those in the control group [(256.49±62.13) ng/L vs. (294.18±60.39) ng/L, (42.58±6.15) ng/L vs. (51.30±6.44) ng/L, and (41.08±6.13) ng/L vs. (49.87±6.34) ng/L], with statistical differences (t=2.38, 5.36, and 5.46; all P <0.05). The BCVA's in the observation group and the control group were higher after than before the treatment (F=27.64 and 21.29; both P<0.05). Conclusion　Fundus laser combined with IVR for patients with RVO-ME can effectively reduce the CMT and levels of vitreous cavity related factors, and improve their BCVA.

Key words:

Retinal vein occlusion secondary to macular edema, Intravitreal injection of ranibizumab, Laser therapy, Fundus, Efficacy

摘要：

目的　探讨眼底激光联合玻璃体腔注射雷珠单抗（IVR）治疗视网膜静脉阻塞继发性黄斑水肿（RVO-ME）患者的临床疗效。方法　选取2019年3月至2022年5月于济南市第二人民医院治疗的60例RVO-ME患者作为研究对象，根据随机数字表法分为观察组与对照组，各30例。观察组男16例，女14例，年龄（54.66±2.31）岁；对照组男15例，女15例，年龄（54.70±2.29）岁。两组患者均予以眼底激光治疗，观察组在此基础上联合使用IVR治疗，比较观察两组患者的黄斑中心凹厚度（CMT）、玻璃体腔相关因子水平变化、最佳矫正视力（BCVA）、中央脉络膜厚度（CCT）以及疾病相关并发症情况。统计学方法采用t检验、χ²检验。结果　治疗后观察组与对照组患者CMT值较治疗前均有所降低（F=501.71、303.62，均P<0.05），治疗后两组各时间点（治疗后1周、1个月、3个月）CMT值比较，差异均有统计学意义（t=11.37、t=6.71、t=5.29，均P<0.05）。治疗后两组患者玻璃体腔内血管内皮生长因子（VEGF）、白介素-6（IL-6）、白介素-8（IL-8）水平较治疗前均有所下降，观察组VEGF、IL-6、IL-8水平均低于对照组［（256.49±62.13）ng/L比（294.18±60.39）ng/L、（42.58±6.15）ng/L比（51.30±6.44）ng/L、（41.08±6.13）ng/L比（49.87±6.34）ng/L］，差异均有统计学意义（t=2.38、5.36、5.46，均P <0.05）。观察组与对照组治疗后患者BCVA值较治疗前均有所升高（F=27.64、21.29，均P<0.05）。结论　采用眼底激光联合IVR治疗RVO-ME患者能够有效降低CMT值及玻璃体腔内相关因子水平，提高BCVA值。

关键词:

视网膜静脉阻塞继发性黄斑水肿, 玻璃体腔注射雷珠单抗, 激光治疗, 眼底, 疗效

Chen Lili, Zhu Chengbao.

Fundus laser combined with intravitreal injection of ranibizumab for patients with retinal vein occlusion secondary to macular edema [J]. International Medicine and Health Guidance News, 2023, 29(12): 1703-1707.

陈丽丽朱成宝.

眼底激光联合IVR治疗RVO-ME患者的疗效观察 [J]. 国际医药卫生导报, 2023, 29(12): 1703-1707.

References

[1] 白小芳,赵芃芃,秦梅,等.雷珠单抗联合Ozurdex治疗视网膜分支静脉阻塞继发黄斑水肿的疗效观察[J].眼科新进展,2022,42(5):394-398.DOI:10.13389/j.cnki.rao.2022.0080.
[2] 谷裕,陈振东,卞栏焰,等.青少年近视患者屈光度与视网膜厚度及黄斑血流的相关性研究[J].国际医药卫生导报,2022,28(14):2002-2005.DOI:10.3760/cma.j.issn. 1007-1245.2022.14.017.
[3] 夏洋,周吉林,黄永健,等.康柏西普联合激光光凝治疗视网膜分支静脉阻塞继发黄斑水肿患者远期视力恢复的影响因素研究[J].眼科新进展,2021,41(2):174-177.
[4] Sangroongruangsri S,Ratanapakorn T,Wu O,et al.Comparative efficacy of bevacizumab, ranibizumab, and aflibercept for treatment of macular edema secondary to retinal vein occlusion: a systematic review and network meta-analysis[J].Expert Rev Clin Pharmacol,2018,11(9):903-916.DOI:10.1080/17512433.2018.1507735.
[5] 林翎,卢毓敏,马胜生.雷珠单抗联合眼底激光治疗糖尿病视网膜病变的疗效[J].实用医学杂志,2021,37(20):2660-2664.DOI:10.3969/j.issn.1006-5725.2021.20.018.
[6] 赵娟,毕晓达,司艳芳,等.雷珠单抗注射液治疗非缺血型视网膜分支静脉阻塞黄斑水肿患者的临床研究[J].中国临床药理学杂志,2021,37(11):1330-1332.DOI:10.13699/j.cnki.1001-6821.2021.11.007.
[7] 马恒哲.雷珠单抗对视网膜分支静脉阻塞继发黄斑水肿患者视网膜血流密度的影响[J].眼科新进展,2021,41(9):874-878.DOI:10.13389/j.cnki.rao.2021.0183.
[8] Lashay A,Riazi-Esfahani H,Mirghorbani M,et al.Intravitreal medications for retinal vein occlusion: Systematic review and meta-analysis[J].J Ophthalmic Vis Res,2019,14(3):336-366.DOI:10.18502/jovr.v14i3.4791.
[9] Sakanishi Y,Yasuda K,Morita S,et al.Twenty-four-month results of intravitreal aflibercept for macular edema due to branch retinal vein occlusion[J].Jpn J Ophthalmol,2021,65(1):63-68.DOI:10.1007/s10384-020-00785-6.
[10] 李翠,梁娟.康柏西普联合周边视网膜选择性光凝治疗视网膜静脉阻塞继发黄斑水肿的疗效观察[J].实用医院临床杂志,2020,17(6):153-156.DOI:10.3969/j.issn.1672-6170. 2020.06.045.
[11] Rao J,Wu N,Qu X,et al.The role of serum inﬂammation-based factors in anti-vascular endothelial growth factor treatment for macular edema secondary to retinal vein occlusion and its subtypes[J].Ophthalmic Res,2021,64(2):237-245.DOI:10.1159/000509171.
[12] 浦利军,承伟,顾晖晖,等.不同激光光凝治疗时机联合玻璃体注射康柏西普治疗视网膜中央静脉阻塞继发黄斑水肿的有效性及安全性[J].中国老年学杂志,2020,40(10):2124-2127.DOI:10.3969/j.issn.1005-9202.2020.10.034.
[13] Gerding H.Results of a meta-analysis on intravitreal anti-VEGF treatment of macular oedema secondary to branch retinal vein occlusion (BRVO)[J].Klin Monbl Augenheilkd,2017,234(4):551-555.DOI:10.1055/s-0042-123025.
[14] Khayat M,Williams M,Lois N.Ischemic retinal vein occlusion: characterizing the more severe spectrum of retinal vein occlusion[J].Surv Ophthalmol,2018,63(6):816-850.DOI:10.1016/j.survophthal.2018.04.005.
[15] 袁昱,王晶晶.抗VEGF与激光治疗非缺血性视网膜分支静脉阻塞继发黄斑水肿的临床对比研究[J].眼科,2020,29(3):209-213.DOI:10.13281/j.cnki.issn.1004-4469. 2020.03.010.
[16] 吴豪,王菁,陈茜,等.中药联合抗VEGF药物治疗视网膜静脉阻塞性黄斑水肿的疗效观察[J].时珍国医国药,2020,31(1):117-120.DOI:10.3969/j.issn.1008-0805.2020.01.038.
[17] 曾凤.雷珠单抗及微脉冲激光治疗视网膜静脉阻塞继发黄斑水肿[J].中华眼外伤职业眼病杂志,2020,42(4):306-311.DOI:10.3760/cma.j.cn116022-20190927-00269.
[18] 周瑞,陈娟,林思勇.视网膜分支静脉阻塞继发黄斑水肿玻璃体注射雷珠单抗不同治疗方案的疗效对比[J].眼科,2020,29(1):63-67.DOI:10.13281/j.cnki.issn. 1004-4469.2020.01.012.
[19] Staurenghi G,Lai TYY,Mitchell P,et al.Efficacy and safety of ranibizumab 0.5 mg for the treatment of macular edema resulting from uncommon causes: Twelve-month findings from PROMETHEUS[J].Ophthalmology,2018,125(6):850-862.DOI:10.1016/j.ophtha.2017.12.002.
[20] Suzuki N,Hirano Y,Tomiyasu T,et al.Retinal hemodynamics seen on optical coherence tomography angiography before and after treatment of retinal vein occlusion[J].Invest Ophthalmol Vis Sci,2016,57(13):5681-5687.DOI:10.1167/iovs-16-20648.
[21] 杨静.雷珠单抗联合眼底激光治疗对糖尿病性黄斑水肿患者视力状况及黄斑水肿消退率的影响[J].哈尔滨医药,2021,41(6):81-82.DOI:10.3969/j.issn.1001-8131. 2021.06.040.